A PYMNTS Company

Servia, Teva and others called out for generic-blocking

By  |  July 30, 2012

French pharmaceutical company Servia as well as generic producers including Israel’s Teva received formal objections from the European Commission concerning alleged entry delay of the generic form of cardiovascular drug perindopril. By both buying up rare technology needed to create the drug and settling out of court with would-be generic producers, the Commission believes Servier abused its dominant market position by restricting competitive business. Similar pay-for-delay practices were denounced only a few days ago in the Commission’s objections issued to pharmaceutical powerhouse Lundbeck.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full content: EU

     

    Related content:  The EC Pharmaceutical Inquiry: Behind the Headlines, What is the Real Story on Innovation and Generic Competition in Pharmaceuticals?

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.